Health Care • Biotechnology: Pharmaceutical Preparations
$1.37 ▼ -0.05
(-3.52%)
MKT CAP: $111.3M • VOL: 310.7K
52W L $1 52W H $4
ROARABLE / RQD
D- • 42/100
PIOTROSKI
1 / 9
EQ // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $41.1M | $36.1M |
| YoY Revenue Growth % | — | +13.9% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$23.6M | -$8.3M | -$14.5M |
| Operating Margin % | — | -20.1% | -40.2% |
| Net Income (GAAP) | -$22.4M | -$8.1M | -$13.3M |
| EBITDA (Normalized) | -$23.6M | -$8.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$22.7M | -$19.0M | -$21.8M |
| Capital Expenditures (CapEx) | $48.0K | $85.0K | — |
| Free Cash Flow (FCF) | -$22.8M | -$19.1M | -$21.8M |
| FCF Margin % | — | -46.5% | -60.4% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $30.3M | $18.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $28.6M | $19.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR EQ.